Chiral
drugs are of great significance in drug development and
life science because one pair of enantiomers has a different combination
mode with target biological active sites, leading to a vast difference
in physical activity. Metal–organic framework (MOF)-based chiral
hybrid materials with specific chiral sites have excellent applications
in the highly effective sensing of drug enantiomers. Sitagliptin and
clonidine are effective curing drugs for controlling diabetes and
hypertension, while insulin and norepinephrine are the biomarkers
of these two diseases. Excessive use of sitagliptin and clonidine
can cause side effects such as stomach pain, nausea, and headaches.
Herein, through post-synthetic strategy, MOF-based chiral hybrid material Eu-BTB@
d
-carnitine (H3BTB = 1,3,5-benzenetrisbenzoic acid) was synthesized. Eu-BTB@
d
-carnitine has
dual emission peaks at 417 and 616 nm when excited at 330 nm. Eu-BTB@
d
-carnitine can
be applied in luminescent recognition toward sitagliptin and clonidine
with high sensitivity and low detection limit (for sitagliptin detection, K
sv is 7.43 × 106 [M–1]; for clonidine detection, K
sv is 9.09
× 106 [M–1]; limit of detection
(LOD) for sitagliptin is 10.21 nM, and LOD of clonidine is 8.34 nM).
In addition, Eu-BTB@
d
-carnitine can further realize highly sensitive detection of insulin in human
fluids with a high K
sv (2.08 × 106 [M–1]) and a low LOD (15.48 nM). On the
other hand, norepinephrine also can be successfully discriminated
by the hybrid luminescent platform of Eu-BTB@
d
-carnitine and clonidine with a high K
sv value of 4.79 × 106 [M–1] and a low LOD of 8.37 nM. As a result, the chiral
hybrid material Eu-BTB@
d
-carnitine can be successfully applied in the highly effective ratiometric
sensing of curing drugs and biomarkers for diabetes and hypertension.